- Home
- PHUN vs VTGN Comparison
PHUN vs VTGN Comparison
Compare PHUN & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- VTGN
- Stock Information
- Founded
- PHUN 2009
- VTGN 1998
- Country
- PHUN United States
- VTGN United States
- Employees
- PHUN N/A
- VTGN N/A
- Industry
- PHUN EDP Services
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- VTGN Health Care
- Exchange
- PHUN Nasdaq
- VTGN Nasdaq
- Market Cap
- PHUN 89.7M
- VTGN 72.4M
- IPO Year
- PHUN N/A
- VTGN N/A
- Fundamental
- Price
- PHUN $4.34
- VTGN $2.40
- Analyst Decision
- PHUN Strong Buy
- VTGN
- Analyst Count
- PHUN 3
- VTGN 0
- Target Price
- PHUN $13.00
- VTGN N/A
- AVG Volume (30 Days)
- PHUN 1.5M
- VTGN 198.6K
- Earning Date
- PHUN 11-07-2024
- VTGN 02-11-2025
- Dividend Yield
- PHUN N/A
- VTGN N/A
- EPS Growth
- PHUN N/A
- VTGN N/A
- EPS
- PHUN N/A
- VTGN N/A
- Revenue
- PHUN $3,537,000.00
- VTGN $876,000.00
- Revenue This Year
- PHUN N/A
- VTGN N/A
- Revenue Next Year
- PHUN $93.33
- VTGN N/A
- P/E Ratio
- PHUN N/A
- VTGN N/A
- Revenue Growth
- PHUN N/A
- VTGN 8.08
- 52 Week Low
- PHUN $2.85
- VTGN $2.38
- 52 Week High
- PHUN $24.50
- VTGN $5.86
- Technical
- Relative Strength Index (RSI)
- PHUN 43.55
- VTGN 32.18
- Support Level
- PHUN $4.17
- VTGN $2.38
- Resistance Level
- PHUN $4.78
- VTGN $2.53
- Average True Range (ATR)
- PHUN 0.28
- VTGN 0.13
- MACD
- PHUN 0.05
- VTGN -0.01
- Stochastic Oscillator
- PHUN 25.01
- VTGN 0.96
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.